Open Trials- September 2020

Breast Cancer Trials:
A study of xentuzumab + everolimus and exemestane VS everolimus and exemestane in post-menopausal women with HR+ / HER2 – metastatic breast cancer and non-visceral disease (Xenera 1)

A study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate, VS Treatment of Investigator’s Choice for HER2 +, Unresectable and/or Metastatic Breast Cancer in Subjects Pretreated with Prior Standard of Care therapies including T-DM1 (DESTINY-Breast 02)

A Prospective Registry study to Evaluate the Effect of the DCISionRT test on Treatment Decisions in Patient with DCIS Following Breast Conserving Therapy

A Study of Tucatinib vs. Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for patients with
Advanced of Metastatic HER2+ Breast Cancer

Evaluation of IPI-549 Combined with Front-line Treatments in Pts. With Triple-Negative Breast Cancer or
Renal Cell Carcinoma

Biliary Tract Cancer Trials:
A Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alpha (M7824) in Participant with 1L Biliary Tract
Cancer (BTC)

Lung Cancer Trials:

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

A Study of Pembrolizumab (Keytruda) + Lenvatinib or placebo for treatment Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC) with TPS ≥ 1% (LEAP 007)

Durvalumab vs Placebo with Stereotactic Body Radiation Therapy in Early Stage Unresected Non-Small Cell
Lung Cancer Patients (PACIFIC-4)

Prospective Clinicogenomic Program

Lymphoma Trials:

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin’s Lymphoma (UNITY-NHL)

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4)

Prostate Cancer Trials:
A Study of Talazoparib + Enzalutamide vs Enzalutamide in Metastatic Castration-Resistant
Prostate Cancer(Talapro-2)

Urothelial Cancer Trials:
Study of Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherpay, vs. Chemotherapy
Alone in Untreated Locally Advanced or MetastaticUrothelial Cancer (EV-302)